Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

New York University researchers say a simple, gene-based blood test has shown to be highly accurate in predicting whether ...

Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

A Swiss drug giant has gotten the message from President Trump’s tariff threats. Novartis said Thursday it will spend $23 ...

A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S.

Swiss pharmaceutical giant Novartis announced it will spend $23 billion to build and expand 10 facilities in the United ...

It joins a growing number of multinational drug companies to announce investments in the US. Read more at straitstimes.com.